Youth Empowerment - Session 4
Our meeting will take place in two sections. Session #1: AI and Healthcare: the New Normal—Mustafa Husain, M.D. and Session #2: Advances in Biotech—Thanos Papa Ioannou. Our moderator will be Sourav Sinha.
Our meeting will take place in two sections. Session #1: AI and Healthcare: the New Normal—Mustafa Husain, M.D. and Session #2: Advances in Biotech—Thanos Papa Ioannou. Our moderator will be Sourav Sinha.
Link to the Meeting https://us02web.zoom.us/j/82755463059
Please register in Advance at EVENTBRITE
Please register in Advance at EVENTBRITE
report inside.
Youth Empowerment - Session 4
SESSION #1 - AI and Healthcare: the New Normal
MUSTAFA HUSAIN, M.D.
Mustafa Husain, MD, is currently tenured Professor of Psychiatry Neurology and Internal Medicine, Director of the Neuro-Stimulation Research Lab, and Chief of the Geriatric Psychiatry Division at the University of Texas Southwestern Medical Center at Dallas. Until recently he was Vice Chair for Faculty development at Duke University School of Medicine, Durham NC
He is a graduate of Dow Medical College, Karachi, Pakistan. He received his initial training in the United States at Stanford University, Palo Alto, CA. He completed his residency at the USC and continued his research and geriatric fellowships at Duke University Medical Center in Durham, NC. Dr Husain has published numerous peer-reviewed articles in national and international scientific journals, authored several book chapters, including chapter on ECT and Other Neurostimulation Therapies for the new edition of the Kaplan and Saddock’s Text Book of General Psychiatry. He currently serves as a reviewer for major professional journals. He is on the editorial board for the Journal of ECT. Dr. Husain has received several awards including FDA Asian American Accomplishment Award, the Young Investigator Award from NCDEU and 1st Summer Research Institute Award from NIMH. He has served as Grant Reviewer on NIMH study sections and on NIMH Conte Center as well as Welcome Trust , London, UK
Dr Husain is involved in training, education, and research in general psychiatry; aging and geriatric issues; and novel treatments for major depressive disorder, including magnetic stimulation therapy vagus nerve stimulation and deep brain stimulation. He has received several federally funded grants as well of multiple Foundation Studies.
SESSION #2 - Advances in Biotech
THANOS PAPA IOANNOU
Thanos has focused his career on solving exceptionally hard problems using mathematics. His career has spanned academia, quantitative investing, and computational drug discovery.
As a Principal at Roivant Sciences, Thanos leads investment in and incubation of technology companies that sit at the intersection of computational methods, drug discovery, and eventual clinical development. Founded in 2014, the tech-enabled biopharma has raised over $5 billion in aggregate capital from investors including Viking Global Investors and SoftBank Vision Fund to support a pipeline of 45+ investigational drugs across 14 therapeutic areas. Before joining Roivant, Thanos worked in quantitative strategy portfolio management at Ellington Management Group, a multi-billion dollar hedge fund.
Thanos holds a Ph.D. in Mathematics from the University of Chicago and an A.B. in Mathematics from Harvard University. He has published in the fields of p-adic algebraic geometry and semi-definite programming, where he solved the last open machine-learning problem on OpenAI’s Request for Research 2.0.
MUSTAFA HUSAIN, M.D.
Mustafa Husain, MD, is currently tenured Professor of Psychiatry Neurology and Internal Medicine, Director of the Neuro-Stimulation Research Lab, and Chief of the Geriatric Psychiatry Division at the University of Texas Southwestern Medical Center at Dallas. Until recently he was Vice Chair for Faculty development at Duke University School of Medicine, Durham NC
He is a graduate of Dow Medical College, Karachi, Pakistan. He received his initial training in the United States at Stanford University, Palo Alto, CA. He completed his residency at the USC and continued his research and geriatric fellowships at Duke University Medical Center in Durham, NC. Dr Husain has published numerous peer-reviewed articles in national and international scientific journals, authored several book chapters, including chapter on ECT and Other Neurostimulation Therapies for the new edition of the Kaplan and Saddock’s Text Book of General Psychiatry. He currently serves as a reviewer for major professional journals. He is on the editorial board for the Journal of ECT. Dr. Husain has received several awards including FDA Asian American Accomplishment Award, the Young Investigator Award from NCDEU and 1st Summer Research Institute Award from NIMH. He has served as Grant Reviewer on NIMH study sections and on NIMH Conte Center as well as Welcome Trust , London, UK
Dr Husain is involved in training, education, and research in general psychiatry; aging and geriatric issues; and novel treatments for major depressive disorder, including magnetic stimulation therapy vagus nerve stimulation and deep brain stimulation. He has received several federally funded grants as well of multiple Foundation Studies.
SESSION #2 - Advances in Biotech
THANOS PAPA IOANNOU
Thanos has focused his career on solving exceptionally hard problems using mathematics. His career has spanned academia, quantitative investing, and computational drug discovery.
As a Principal at Roivant Sciences, Thanos leads investment in and incubation of technology companies that sit at the intersection of computational methods, drug discovery, and eventual clinical development. Founded in 2014, the tech-enabled biopharma has raised over $5 billion in aggregate capital from investors including Viking Global Investors and SoftBank Vision Fund to support a pipeline of 45+ investigational drugs across 14 therapeutic areas. Before joining Roivant, Thanos worked in quantitative strategy portfolio management at Ellington Management Group, a multi-billion dollar hedge fund.
Thanos holds a Ph.D. in Mathematics from the University of Chicago and an A.B. in Mathematics from Harvard University. He has published in the fields of p-adic algebraic geometry and semi-definite programming, where he solved the last open machine-learning problem on OpenAI’s Request for Research 2.0.
Moderated by:
SOURAV SINHA
Sourav is a Founding Venture Partner & Head of Innovation at the Longevity Vision Fund, the largest longevity-focused venture fund in the world. He leads investments of the $100M fund and advises late-stage companies developing therapeutics, diagnostics, medical devices, and technologies that extend the healthy human lifespan. Sourav has led investments in:
SOURAV SINHA
Sourav is a Founding Venture Partner & Head of Innovation at the Longevity Vision Fund, the largest longevity-focused venture fund in the world. He leads investments of the $100M fund and advises late-stage companies developing therapeutics, diagnostics, medical devices, and technologies that extend the healthy human lifespan. Sourav has led investments in:
• Life Biosciences: Developing several longevity therapies from the world-renowned longevity researcher, Dr. David Sinclair (Harvard Medical School)
• Sigilon Therapeutics: Encapsulated cell therapies developed by Dr. Bob Langer (MIT)
• LyGenesis: Organ regeneration developed by Dr. Eric Lagasse (Univ. of Pittsburgh)
• 4DMT: Next generation gene therapy platform to treat fatal genetic diseases developed by Dr. David Schaffer (Berkeley)
• Freenome: Leading liquid biopsy to diagnose cancer and diseases at their earliest, most treatable stages
• Juvenescence: Anti-aging portfolio company founded by Greg Bailey and Jim Mellon
Sourav previously led Strategy and Special Projects for Celularity—the first spinout of Celgene Corporation. Celularity creates groundbreaking cellular immunotherapies engineered from placental stem cells. He worked dynamically and cross-functionally between scientific, clinical, finance, and business development teams to bring these therapies through late stage clinical trials. Celularity has raised $300+M in venture financing to support its vision to harness the power of living cells to augment biology, immunity, and longevity.
Sourav is the Founder of Oncolinx, an AI/ML Drug Discovery company powered by the most powerful supercomputer in the world solely dedicated to biomedical research. Oncolinx uses AI and ML to develop small molecules targeting several “undruggable” and immunotherapeutic targets such as STAT3 (N-terminal domain), K-Ras, TIGIT, CD155, VISTA, and others. In 2020, was tapped by the NIH COVID-19 Response Team to rapidly develop therapeutics for the global Coronavirus Pandemic.Sourav previously served as Entrepreneur-in-Residence for the Center for Advancing Innovation (CAI), a first-of-its-kind public/private partnership commercializing high-impact inventions from NCI, NIH, NASA, DoD, NSA and other government labs. Over 3 years, Sourav and the CAI spun out 82 companies from the government labs across diverse sectors of biotechnology, aerospace, cleantech, cybersecurity, advanced manufacturing and other high-impact areas.
Sourav is a Global Shaper of the World Economic Forum. He was invited to participate in the 2019 Annual Meeting of the WEF in Davos. Sourav has also been a participant in the Future Investment Initiative, and UNGA where he worked with global leaders to improve the state of the world.Sourav holds an A.B. in Molecular Biology and Biochemistry from Dartmouth College, and is a graduate of Singularity University’s Global Solutions Program. Sourav’s research has been published in top-tier journals and industry textbooks, and he was featured on the Forbes 30 Under 30 list for Healthcare in 2018.
• Sigilon Therapeutics: Encapsulated cell therapies developed by Dr. Bob Langer (MIT)
• LyGenesis: Organ regeneration developed by Dr. Eric Lagasse (Univ. of Pittsburgh)
• 4DMT: Next generation gene therapy platform to treat fatal genetic diseases developed by Dr. David Schaffer (Berkeley)
• Freenome: Leading liquid biopsy to diagnose cancer and diseases at their earliest, most treatable stages
• Juvenescence: Anti-aging portfolio company founded by Greg Bailey and Jim Mellon
Sourav previously led Strategy and Special Projects for Celularity—the first spinout of Celgene Corporation. Celularity creates groundbreaking cellular immunotherapies engineered from placental stem cells. He worked dynamically and cross-functionally between scientific, clinical, finance, and business development teams to bring these therapies through late stage clinical trials. Celularity has raised $300+M in venture financing to support its vision to harness the power of living cells to augment biology, immunity, and longevity.
Sourav is the Founder of Oncolinx, an AI/ML Drug Discovery company powered by the most powerful supercomputer in the world solely dedicated to biomedical research. Oncolinx uses AI and ML to develop small molecules targeting several “undruggable” and immunotherapeutic targets such as STAT3 (N-terminal domain), K-Ras, TIGIT, CD155, VISTA, and others. In 2020, was tapped by the NIH COVID-19 Response Team to rapidly develop therapeutics for the global Coronavirus Pandemic.Sourav previously served as Entrepreneur-in-Residence for the Center for Advancing Innovation (CAI), a first-of-its-kind public/private partnership commercializing high-impact inventions from NCI, NIH, NASA, DoD, NSA and other government labs. Over 3 years, Sourav and the CAI spun out 82 companies from the government labs across diverse sectors of biotechnology, aerospace, cleantech, cybersecurity, advanced manufacturing and other high-impact areas.
Sourav is a Global Shaper of the World Economic Forum. He was invited to participate in the 2019 Annual Meeting of the WEF in Davos. Sourav has also been a participant in the Future Investment Initiative, and UNGA where he worked with global leaders to improve the state of the world.Sourav holds an A.B. in Molecular Biology and Biochemistry from Dartmouth College, and is a graduate of Singularity University’s Global Solutions Program. Sourav’s research has been published in top-tier journals and industry textbooks, and he was featured on the Forbes 30 Under 30 list for Healthcare in 2018.